Skip to main content

Table 1 Demographics

From: Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine

Variable

EUR group ( N=1217)

NE group ( N=800)

Total ( N=2017)

p-value

Age in Years (Mean ± SD)

33.0 ± 9.2

33.4 ± 8.9

33.2 ± 9.1

.3999b

Age <25, n (%)

298 (24.5)

160 (20.0)

458 (22.7)

.0195a

Age ≥25, n (%)

919 (75.5)

640 (80.0)

1559 (77.3)

 

Race, n (%)

   

<.0001a

  Caucasian

1192 (97.9)

573 (71.6)

1765 (87.5)

 

  African

5 (0.4)

51 (6.4)

56 (2.8)

 

  Hispanic

9 (0.7)

150 (18.8)

159 (7.9)

 

  Other

11 (0.9)

24 (3.0)

35 (1.7)

 

Gender, n (%)

    

  Male

702 (57.7)

482 (60.3)

1184 (58.7)

.2673a

  Female

515 (42.3)

318 (39.8)

833 (41.3)

 

Body Weight (kg), Mean (SD)

76.8 (17.6)

82.4 (19.7)

79.0 (18.7)

<.0001b

Height (cm), Mean (SD)

173.8 (9.4)

171.7 (10.0)

173.0 (9.7)

<.0001b

Prior Exposure to Psychostimulants, n (%)

   

  Yes

398 (32.7)

311 (38.9)

709 (35.2)

.0049a

  No

819 (67.3)

489 (61.1)

1308 (64.8)

 

ADHD Subtype, n (%)

  

.0001a

  Inattentive

298 (24.5)

168 (21.0)

466 (23.1)

 

  Hyperactive/Impulsive

40 (3.3)

7 (0.9)

47 (2.3)

 

  Combined

872 (71.7)

623 (77.9)

1495 (74.1)

 

Family History of ADHD, n (%)

   

  Children

308 (25.3)

159 (19.9)

467 (23.2)

.0343a

  Mother

63 (5.2)

46 (5.8)

109 (5.4)

.2753a

  Father

104 (8.5)

63 (7.9)

167 (8.3)

.2532a

  Siblings

156 (12.8)

146 (18.3)

302 (15.0)

.0043a

  1. Abbreviations: ADHD = attention-deficit/hyperactivity disorder; EUR = European; N = total number of patients; n = number of patients in the specified category; NE = non-European; SD = standard deviation.
  2. ap-values are from Fisher’s exact test.
  3. bp-values are from t-test.